🚀 VC round data is live in beta, check it out!
Denali Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Denali Therapeutics and similar public comparables like Gland Pharma, Xenon Pharmaceuticals, Santen Pharmaceutical, BB Biotech and more.
Denali Therapeutics Overview
About Denali Therapeutics
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
Founded
2013
HQ
Employees
422
Website
Sectors
Financials (LTM)
EV
$2B
Denali Therapeutics Financials
Denali Therapeutics reported last 12-month revenue of $15M and negative EBITDA of ($512M).
In the same LTM period, Denali Therapeutics generated $15M in gross profit, ($512M) in EBITDA losses, and had net loss of ($500M).
Revenue (LTM)
Denali Therapeutics P&L
In the most recent fiscal year, Denali Therapeutics reported revenue of — and EBITDA of ($519M).
Denali Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $15M | XXX | — | XXX | XXX | XXX |
| Gross Profit | $15M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 96% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($512M) | XXX | ($519M) | XXX | XXX | XXX |
| EBITDA Margin | (3371%) | XXX | — | XXX | XXX | XXX |
| EBIT Margin | (3572%) | XXX | — | XXX | XXX | XXX |
| Net Profit | ($500M) | XXX | ($513M) | XXX | XXX | XXX |
| Net Margin | (3297%) | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Denali Therapeutics Stock Performance
Denali Therapeutics has current market cap of $3B, and enterprise value of $2B.
Market Cap Evolution
Denali Therapeutics' stock price is $21.00.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $3B | 0.0% | XXX | XXX | XXX | $-3.28 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialDenali Therapeutics Valuation Multiples
Denali Therapeutics trades at 163.1x EV/Revenue multiple, and (4.8x) EV/EBITDA.
EV / Revenue (LTM)
Denali Therapeutics Financial Valuation Multiples
As of April 5, 2026, Denali Therapeutics has market cap of $3B and EV of $2B.
Equity research analysts estimate Denali Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Denali Therapeutics has a P/E ratio of (6.6x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 163.1x | XXX | — | XXX | XXX | XXX |
| EV/EBITDA | (4.8x) | XXX | (4.8x) | XXX | XXX | XXX |
| EV/EBIT | (4.6x) | XXX | (4.5x) | XXX | XXX | XXX |
| EV/Gross Profit | 169.1x | XXX | — | XXX | XXX | XXX |
| P/E | (6.6x) | XXX | (6.4x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (5.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Denali Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Denali Therapeutics Margins & Growth Rates
Denali Therapeutics' revenue in the last 12 month grew by 419%.
Denali Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.3M for the same period.
Denali Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 419% | XXX | (100%) | XXX | XXX | XXX |
| EBITDA Margin | (3371%) | XXX | — | XXX | XXX | XXX |
| EBITDA Growth | (4%) | XXX | (6%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.3M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 945% | XXX | — | XXX | XXX | XXX |
| R&D Expenses to Revenue | 2715% | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Denali Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Gland Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Xenon Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Santen Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| BB Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| United Laboratories International | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Denali Therapeutics M&A Activity
Denali Therapeutics acquired XXX companies to date.
Last acquisition by Denali Therapeutics was on XXXXXXXX, XXXXX. Denali Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Denali Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialDenali Therapeutics Investment Activity
Denali Therapeutics invested in XXX companies to date.
Denali Therapeutics made its latest investment on XXXXXXXX, XXXXX. Denali Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Denali Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Denali Therapeutics
| When was Denali Therapeutics founded? | Denali Therapeutics was founded in 2013. |
| Where is Denali Therapeutics headquartered? | Denali Therapeutics is headquartered in United States. |
| How many employees does Denali Therapeutics have? | As of today, Denali Therapeutics has over 422 employees. |
| Who is the CEO of Denali Therapeutics? | Denali Therapeutics' CEO is Ryan J. Watts. |
| Is Denali Therapeutics publicly listed? | Yes, Denali Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Denali Therapeutics? | Denali Therapeutics trades under DNLI ticker. |
| When did Denali Therapeutics go public? | Denali Therapeutics went public in 2017. |
| Who are competitors of Denali Therapeutics? | Denali Therapeutics main competitors are Gland Pharma, Xenon Pharmaceuticals, Santen Pharmaceutical, BB Biotech. |
| What is the current market cap of Denali Therapeutics? | Denali Therapeutics' current market cap is $3B. |
| What is the current revenue of Denali Therapeutics? | Denali Therapeutics' last 12 months revenue is $15M. |
| What is the current revenue growth of Denali Therapeutics? | Denali Therapeutics revenue growth (NTM/LTM) is 419%. |
| What is the current EV/Revenue multiple of Denali Therapeutics? | Current revenue multiple of Denali Therapeutics is 163.1x. |
| Is Denali Therapeutics profitable? | No, Denali Therapeutics is not profitable. |
| What is the current EBITDA of Denali Therapeutics? | Denali Therapeutics has negative EBITDA and is not profitable. |
| What is Denali Therapeutics' EBITDA margin? | Denali Therapeutics' last 12 months EBITDA margin is (3371%). |
| What is the current EV/EBITDA multiple of Denali Therapeutics? | Current EBITDA multiple of Denali Therapeutics is (4.8x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.